Assembly Biosciences公司展开高层领导团队

StephenW

Assembly Biosciences Expands Senior Leadership Team
Globe Newswire
January 11, 2016: 07:30 AM ET

INDIANAPOLIS, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced several new senior level hires across the organization. The added team members include Richard Colonno, PhD, as Chief Scientific Officer; Thomas Rollins as Chief Development Officer and Head of the Microbiome Program; Elizabeth Haber Lacy as General Counsel and Vice President of Legal Operations; Wayne Herber, PhD, as Vice President, Biological Manufacturing and Quality; Hongmei Huang, PhD, as Vice President, Information Technology and Informatics; Leping Li, PhD, as Vice President, Discovery; Micah Mackison as Vice President, Corporate Development and Strategy; Eric Ruby as Vice President, Regulatory Affairs and Quality Assurance and Simon Haydar, PhD, as Senior Director, Discovery.

“The exceptional quality of these incoming senior managers adds significant depth and experience to the innovative science and technical approaches we are pursuing at Assembly to cure HBV and leverage the microbiome to treat infectious diseases,” said Assembly Chief Executive Officer Derek Small. “With our team largely complete and cash reserves on hand projected to fund our progress for two years, we anticipate initiating clinical trials in the second half of 2016 with our microbiome therapy for recurrent CDI and our lead CpAM antiviral compound for the treatment of HBV.”

Chief Scientific Officer Richard Colonno, PhD, is an internationally recognized expert with over 30 years of experience in antiviral drug discovery and development. He joins Assembly from Presidio Pharmaceuticals, where he served as CSO and directed the company’s hepatitis C (HCV) antiviral programs, including the discovery and development of the HCV NS5A inhibitor ravidasvir. Prior to Presidio, Dr. Colonno was Vice President, Infectious Diseases Drug Discovery at Bristol-Myers Squibb, where he played a pivotal role in building the company’s existing antiviral franchise, including the discovery, development and approval of entecavir (Baraclude®) for HBV and atazanavir (Reyataz®) for HIV. Earlier, he was Senior Director of Antiviral Research at Merck Research Labs following research positions at DuPont’s Experimental Station and the Roche Institute of Molecular Biology. Dr. Colonno received a PhD in Microbiology from the University of Kansas and has co-authored more than 160 scientific articles.

Chief Development Officer and Head of the Microbiome Program Thomas Rollins joins Assembly from anti-infective drug developer Cubist Pharmaceuticals, where he was Senior Vice President and Global Head, Program and Portfolio Management, chairing the team overseeing global product development. During his tenure, Mr. Rollins oversaw the global development and commercialization of the anti-bacterial drugs Sivestro® and Zerbaxa®, and helped transform Cubist into a multi-program, multi-product company. Previously, Mr. Rollins was Senior Vice President, Program Management at Sunovion Pharmaceuticals. At Sepracor, as Senior Vice President of Development, Mr. Rollins established an efficient and productive semi-virtual drug development organization that advanced Lunesta® from IND through NDA submission in just 42 months. Earlier in his career, Mr. Rollins served as a researcher before moving to Project Management at Merck, where he was co-team leader for a number of major global products, including Crixivan®, the first HIV protease inhibitor, and the pioneering osteoporosis drug Fosamax®. Mr. Rollins received an MBA from Rutgers University and BS and MS degrees from Michigan State University.

General Counsel and Vice President of Legal Operations Elizabeth Haber Lacy was formerly a partner in the Indianapolis office of law firm Barnes & Thornburg, specializing in corporate and entrepreneurial services, venture and corporate financings and corporate transactions. Previously, she was a partner in the corporate practice at Indianapolis legal firm Leagre, Chandler & Millard. Earlier in her career, Ms. Lacy worked at Chicago law firms Kirkland & Ellis and Jones, Day, Reavis & Pogue. Ms. Lacy is a member of the Indiana and Illinois state bars. She received an AB in public policy from Duke University and a JD from the Case Western Reserve University School of Law, where she graduated summa cum laude and was elected to the Order of the Coif. Ms. Lacy was selected for inclusion in The Best Lawyers in America® in 2011-2015 and was named "Lawyer of the Year" in 2013 in the area of venture capital law.

Vice President, Biological Manufacturing & Quality Wayne Herber, PhD, is a microbiologist with almost 30 years of experience in the scale-up and manufacture of a wide range of vaccines and other biologics, as well as antibiotics and secondary metabolites. Prior to Assembly, Dr. Herber was Senior Director, Manufacturing Science & Technology at AstraZeneca Biologics. Previously, Dr. Herber was Vice President, Process and Product Development at Auxilium Pharmaceuticals. For more than 20 years, Dr. Herber held positions of increasing responsibility at Merck, starting as Senior Research Microbiologist and progressing to Senior Director for Bioprocess R&D, Fermentation & Cell Culture, and ultimately Director/Distinguished Scientist for Vaccine Process Development. He received a BS from the University of Delaware and a PhD in microbiology from Rutgers University. Dr. Herber completed post-doctoral studies at Georgetown University School of Medicine.

Vice President, Information Technology and Informatics Hongmei Huang, PhD, was most recently Senior Director and Global Head of Research IT/Informatics at Janssen (Johnson & Johnson), where she oversaw scientific data management and IT services. Previously, Dr. Huang was Director and Site Head, Novartis Research IT, where she was responsible for the development and delivery of informatics systems, infrastructure and client solutions for the Infectious Disease and Oncology units. As Associate Director, R&D Informatics at Exelixis, Dr. Huang spearheaded informatics support for clinical development activities. As Associate Director/Site Area Head, Global Research Informatics at Roche, Dr. Huang provided strategic informatics services for discovery and preclinical safety. At Array BioPharma, Dr. Huang established a fully integrated research informatics platform. She received a BS at Beijing University, an MS from the University of Michigan and a PhD in organic chemistry at the Scripps Research Institute.

Vice President, Discovery Leping Li, PhD, has more than 20 years of experience in drug discovery and early development, leading project teams and advancing multiple programs from early lead identification to advanced clinical development in infectious diseases, cancer and metabolic disorders. Dr. Li joins Assembly from antiviral drug developer Presidio Pharmaceuticals, where he was Vice President of Chemistry and inventor of the HCV NS5A inhibitor ravidasvir. Previously, he was Scientific Director in Medicinal Chemistry at Amgen, where he received the 2004 Robert A. Swanson Distinguished Employee Award. Before Amgen, Dr. Li served as a Research Investigator at Abbott Laboratories. Dr. Li obtained a BS degree from Shandong University in China.  He earned a PhD in organic chemistry at Rice University and conducted postdoctoral research at Stanford University.

Vice President, Corporate Development and Strategy Micah Mackison has over 15 years of pharmaceutical and life sciences experience in corporate development and strategy, mergers and acquisitions and finance. Prior to Assembly, he was Senior Director, Corporate Investment–Life Sciences for Jabil, where he was responsible for healthcare M&A and venture investments. Previously, Mr. Mackison founded and served as Managing Director of Oakridge Bioventures, a pharmaceutical strategy and M&A advisory firm, where he advised and co-founded startup companies. Previously, Mr. Mackison served as Divisional Director of Corporate Strategy and Senior Director, New Ventures at Lundbeck in Copenhagen. Prior to Lundbeck, Mr. Mackison was Director, Corporate Development and M&A with Ovation Pharmaceuticals, which was acquired by Lundbeck in 2009. Earlier in his career, Mr. Mackison held positions of increasing responsibility in finance at Pfizer and Eli Lilly. He earned a BS in finance from Indiana University.

Vice President, Regulatory Affairs and Quality Assurance Eric Ruby has more than 20 years of experience in managing regulatory strategy and the regulatory review process at leading biotechnology companies, where he has had responsibility for more than 15 drug development programs. Prior to Assembly, Mr. Ruby was Vice President of Regulatory Affairs at Presidio Pharmaceuticals, where he oversaw regulatory strategies for the company’s HCV development programs. Previously, he was Senior Director, Regulatory Affairs at Alnylam Pharmaceuticals and at Vertex Pharmaceuticals. At Vertex, Mr. Ruby led global regulatory activities for the HCV drug Incivek™ up to Phase III. Earlier in his career, Mr. Ruby was a chemistry reviewer and manager for drug metabolism and pharmacokinetic reviews at the US Food and Drug Administration. Mr. Ruby earned a BA from Harvard University and an MS degree from the University of California, Berkeley.

Senior Director, Discovery, Simon Haydar, PhD, has broad experience in the operational and strategic management of early stage drug research. Dr. Haydar joins Assembly from Eli Lilly & Co., where he was a Senior Research Advisor before serving as Director, then Senior Director of External Innovation R&D Emerging Markets unit. Prior to Lilly, Dr. Haydar was Chief Scientist for HIV Infectious Diseases at GlaxoSmithKline. Earlier in his career he was a medicinal chemistry Group Leader at Wyeth Pharmaceuticals and a Senior Research Scientist at Albany Molecular Research. Dr. Haydar is the co-author of many patents, as well as numerous scientific publications and presentations. He earned a PhD in organic chemistry at the University of Vermont and completed a postdoctoral fellowship at Florida State University.

About Assembly Biosciences

Assembly Biosciences, Inc. is a public biotechnology company developing novel oral therapies for the cure of intractable infectious diseases, currently focusing on hepatitis B virus (HBV) and C. difficile infections (CDI). Assembly’s HBV-Cure research team is discovering and developing multiple drug candidates that address both upstream and downstream targets in the HBV lifecycle for possible use in combination therapy. The goal is to eradicate, rather than just treat, HBV infection with an orally-administered regimen. Assembly has built a senior scientific team that has over 30 years of combined experience working on HBV. The company’s CDI program is focused on the targeted delivery of microbiome-based therapies in a novel oral formulation to treat recurrent CDI patients. Assembly has a proprietary delivery system, GemicelTM, which allows for targeted delivery of selected GMP-manufactured bacteria to the lower gastrointestinal tract, and it has built a team of world-class microbiome scientists from academia and industry to help advance this innovative program. For more information visit assemblybio.com.   

StephenW

大会Biosciences公司展开高层领导团队
中国商业电讯
2016年1月11日：07:30上午ET

印第安纳波利斯，2016年1月11日（GLOBE NEWSWIRE） - 装配生物科学公司（纳斯达克股票代码：ASMB），一家生物技术公司开发的传染病包括乙肝病毒（HBV）和艰难梭菌的治疗护理（CDI）的感染，今天宣布了一些新的高层聘用整个组织。添加的团队成员包括理查德·科隆诺，博士，首席科学官;托马斯·罗林斯担任首席开发官和微生物组项目负责人;伊丽莎白·哈伯拉齐作为总法律顾问兼法律运营副总裁;韦恩数量锐减，博士，副总裁，生物制造和质量;红梅黄，博士，副总裁，信息技术和信息;乐平李，博士，副总裁，探索;弥迦Mackison为副总裁，公司发展和战略;埃里克红宝石作为副总裁，法规事务和质量保证和西蒙·海达尔，博士，担任高级主管，发现。

“这些进入的高级管理人员的卓越品质增加了显著的深度和经验，创新的科学和我们所追求的，在大会治愈乙肝病毒，并利用微生物来治疗感染性疾病的技术方法，”集结号首席执行官德里克·小称。 “手头有我们的团队基本完成和现金储备预计两年资助我们的进步，我们预计开始于2016年下半年的临床试验我们的微生物疗法治疗复发性CDI和我们对乙肝的治疗铅CPAM抗病毒化合物。 “

首席科学官理查德科隆诺，博士，是国际公认的专家，拥有超过30年的抗病毒的药物发现和开发经验。他距离Presidio制药公司，在那里他担任CSO和指导公司的丙型肝炎（HCV）的抗病毒方案，包括HCV NS5A抑制剂ravidasvir的发现和开发联接大会。在此之前要塞，科隆诺博士担任副总裁，传染病药物研发在施贵宝公司，在那里他建立了公司现有的抗病毒药物的专营权，包括乙肝病毒的发现，开发和恩替卡韦的批准（Baraclude®）发挥了关键作用与阿扎那韦（Reyataz®）为HIV。此前，他是抗病毒研究之后，在杜邦公司的试验站与分子生物学的罗氏研究所从事研究工作的高级总监默克研究实验室。科隆诺博士获得博士学位在微生物学，从堪萨斯大学和人合着了160多篇科学论文。

首席开发官和微生物组计划托马斯·罗林斯负责人加盟大会从抗感染药物开发Cubist Pharmaceuticals公司，在那里他是高级副总裁兼全球负责人，项目与项目组合管理，主持团队负责全球产品开发。在他任职期间，罗林斯先生负责监督抗菌药物Sivestro®和Zerbaxa®的全球开发和商业化，并帮助改变了立体主义到多项目，多产品的公司。此前，罗林斯先生为高级副总裁，在Sunovion制药项目管理。在Sepracor公司，作为发展的高级副总裁罗林斯先生成立，在短短42个月先进Lunesta®从IND通过NDA提交一个有效的和富有成效的半虚拟药物开发组织。在他的职业生涯早期，罗林斯先生曾担任研究员移动到项目管理默克公司，在那里他是合作团队的领导者为一些重大的全球性产品，包括Crixivan®，第一个HIV蛋白酶抑制剂的前面，而创业骨质疏松症的药物Fosamax®。罗林斯先生获得了MBA学位罗格斯大学和学士和硕士学位，密歇根州立大学。

总法律顾问及法律伊丽莎白运营副总裁哈伯拉齐前身是律师事务所的Barnes＆Thornburg的印第安纳波利斯办事处的合伙人，专注于企业和创业服务，创业和企业融资和企业交易。此前，她在印第安纳波利斯律师事务所Leagre，钱德勒和米勒德企业实践的合伙人。在她的职业生涯早期，花边女士曾在芝加哥律师事务所凯易和琼斯，日，雷维斯和波格。莱西女士是印第安纳州和伊利诺伊州的酒吧中的一员。她收到了AB公司在美国杜克大学和凯斯西储大学法学院，在那里她毕业以优异成绩，并当选为订单头巾的法学博士公共政策。拉齐女士被选入最佳律师在America®在2011 - 2015年又被评为“律师年度”，2013年风险投资的法律领域。

副总裁，生物制造与质量韦恩数量锐减，博士，是近30年，在规模扩大的范​​围广泛的疫苗和其他生物制品和制造经验，以及抗生素和次生代谢产物的微生物学家。在装配之前，数量锐减博士是高级总监，制造科学与技术，在阿斯利康生物制剂。此前，数量锐减博士担任副总裁，工艺和产品开发，在Auxilium制药。对于超过20年，数量锐减博士举办越来越多的责任，在默克公司，作为启动高级研究微生物学家，发展到高级主管生物加工研发，发酵和细胞培养的位置，并最终导演/杰出科学家疫苗工艺开发。他收到了来自特拉华大学的学士学位和罗格斯大学的微生物学博士学位。数量锐减博士完成博士后研究，在乔治敦大学医学院。

副总裁，信息技术和信息红梅黄，博士，最近是高级主管和IT研究全球主管/信息学在扬森（强生），在那里她负责监督的科学数据管理和IT服务。此前，黄医生是主任和网站负责人，诺华公司IT研究，在那里她负责开发和交付信息学系统，基础设施和客户端解决方案的传染病和肿瘤学单位。作为副总监，研发信息学在Exelixis公司，黄博士带领信息学临床开发活动的支持。作为副主任/地盘面积主管，全球信息学研究罗氏，黄博士提供的战略情报服务发现和临床前安全性。在阵列生物制药，黄教授成立了一个完全集成的研究信息学平台。她获得了学士学位，在北京工业大学，密歇根大学的硕士和有机化学博士学位的斯克里普斯研究所。

副总统，发现乐平李，博士，拥有超过20年的药物发现和早期发展的经验，领先的项目团队，并在感染性疾病，癌症和代谢紊乱推进从早期的领先优势识别多个程序，以先进的临床开发。李博士加盟大会的抗病毒药物开发的Presidio制药公司，担任化学副总裁兼HCV NS5A抑制剂ravidasvir的发明者。此前，他是科学主任在药物化学在安进公司，在那里他获得了2004年罗伯特·A·斯旺森杰出员工奖。安进公司之前，李博士曾担任调查研究雅培制药。李医生获得山东大学在中国的学士学位。他获得有机化学博士学位，在莱斯大学和斯坦福大学进行博士后研究。

副总裁，公司发展和战略弥Mackison拥有超过15年的企业发展和战略，并购和融资制药和生命科学领域的经验。在装配之前，他是高级主管，企业投资，生命科学为捷普，在那里他负责医疗保健并购和风险投资。此前，Mackison先生创办并担任橡树岭BioVentures公司董事总经理，医药战略和并购咨询公司，在那里他建议并共同创立的创业公司。此前，Mackison先生担任公司战略的分区总监，高级总监，新创企业在灵北在哥本哈根举行。在此之前Lundbeck公司，Mackison先生是主任，企业发展和并购与的Ovation制药公司，这是在2009年收购了灵北在他的职业生涯早期，Mackison先生曾在金融辉瑞公司和礼来公司增加责任重大的岗位。他拥有印第安那大学金融学学士学​​位。

副总裁，法规事务和质量保证埃里克·Ruby有超过20年的管理监管战略和监管审查程序，在领先的生物技术公司，在那里他有超过15的药物开发计划责任的经验。在装配之前，红宝石先生法规事务的要塞制药，在那里他负责监管战略，为公司的HCV发展计划部副总裁。此前，他是高级主管，监管事务部Alnylam制药和Vertex制药公司。在顶点，红宝石先生领导的HCV药物Incivek™全球监管活动达到第三阶段。在他的职业生涯早期，红宝石先生是一位化学评论家和管理者的药物代谢和药代动力学评价美国食品和药物管理局。红宝石先生拥有哈佛大学学士学位和加州大学伯克利分校的硕士学位。

高级总监发现，西蒙·海达尔，博士，在早期药物研究的运营和战略管理的丰富经验。盖达尔博士加入大会由礼来公司，在那里他是一个高级研究顾问担任董事，高级则外部创新研发的新兴市场部的总监。此前礼来，盖达尔博士首席科学家艾滋病传染病在葛兰素史克公司。在职业生涯早期，他是一个药物化学组组长，在惠氏制药和高级研究科学家在阿尔巴尼分子研究。海达尔博士是合着的许多专利，以及众多的科学出版物和演示文稿。他获得有机化学博士学位，在美国佛蒙特大学，并完成了在佛罗里达州立大学的博士后奖学金。

关于大会生物科学

大会生物科学公司是一家上市的生物技术公司开发的新型口服疗法为顽固性感染性疾病的治疗，目前重点是乙型肝炎病毒（HBV）和艰难梭菌感染（CDI）。装配的HBV-固化研究小组发现和开发多种候选药物，在用于联合疗法可能用途的HBV生命周期处理上游和下游目标。我们的目标是根除，而不仅仅是治疗，乙肝病毒感染的口服治疗方案。大会已建立了一个高级科研团队，拥有超过30年的经验相结合，致力于乙肝病毒。该公司的CDI方案主要集中在靶向递送的微生物组为基础的治疗中一种新的口服制剂治疗复发患者的CDI。大会有一个专有的输送系统，GemicelTM，允许有针对性的交付选择GMP制造的细菌对下消化道，它已经建立了一个团队来自学术界和工业界的世界级微生物的科学家，以帮助推动这一创新的项目。欲了解更多信息，请访问assemblybio.com。

zgct

好文感谢

zgct

这个公司股票是什么？预估连串因素大涨